Sensor-based cell and tissue screening for personalized cancer chemotherapy

Medical and Biological Engineering and Computing

Volumn 50, Issue 2, 2012, Pages 117-126

  Kleinhans, Regina ^a   Brischwein, Martin ^a   Wang, Pei ^a   Becker, Bernhard ^a   Demmel, Franz ^a   Schwarzenberger, Tobias ^a   Zottmann, Marlies ^a   Wolf, Peter ^a,b   Niendorf, Axel ^c   Wolf, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HP Medizintechnik GmbH   (Germany)

^c Pathologie Hamburg West   (Germany)

Author keywords

Cancer tissue; Cell metabolism; Sensor; Targeted therapy

Indexed keywords

ASSAY METHODS; CANCER CHEMOTHERAPY; CANCER THERAPY; CANCER TISSUES; CANCEROUS TISSUES; CELL METABOLISM; CELLULAR OXYGEN; CHEMOSENSITIVITY; CHLOROACETALDEHYDE; CLINICAL STUDY; CULTURE MAINTENANCE; DOXORUBICIN; EX-VIVO; EXTRACELLULAR; FLUID SYSTEMS; HIGH-CONTENT; INFORMATION CONTENTS; LABEL FREE; METABOLIC ACTIVITY; METABOLIC RATES; MICROREACTION CHAMBERS; OXYGEN CONSUMPTION RATE; REAL TIME; REAL TIME ANALYSIS; SENSOR TESTS; TARGETED THERAPY; TISSUE EXPLANTS;

ASSAYS; CHEMOTHERAPY; DIAGNOSIS; DISEASES; DISSOLVED OXYGEN; METABOLISM; TISSUE; TISSUE CULTURE; TITRATION;

SENSORS;

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; DRUG SCREENING; FEMALE; GENETIC PROCEDURES; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; OXYGEN CONSUMPTION; PERSONALIZED MEDICINE; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; OXYGEN CONSUMPTION; TUMOR CELLS, CULTURED;

EID: 84858775782     PISSN: 01400118     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11517-011-0855-7     Document Type: Article

References (33)

1. Abel U (1992) Chemotherapy of advanced epithelial cancer: a critical review. Biomed Pharmacother 46:439-452 (Pubitemid 23041381)
2. Brischwein M, Grundl D, Zhang X, Wolf B (2009) Finite-element modelling of microphysiometry on cellular specimen, World Congress on Medical Physics and Biomedical Engineering, September 7-12, 2009, Munich, Germany. In: Dössel O, Schlegel WC (eds) IFMBE proceedings, vol 25/VII, Springer, Heidelberg (ISBN 978-3-642-03472-5, S. 30-33)
3. Brischwein M, Motrescu ER, Otto AM, Cabala E, Grothe H, Wolf B (2003) Functional cellular assays with multiparametric silicon sensor chips. Lab Chip 3(4):234-240 (Pubitemid 41646529)
4. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416 (Pubitemid 28193601)
5. Demetrick DJ, Douglas J (2003) Targeting cancer treatment: the challenge of anatomical pathology to the analytical chemist. Analyst 128:995-997 (Pubitemid 37026254)
6. Desar IME, van Herpen CML, van Laarhoven HWM, Barentz JO, Oyen WJG, van der Graaf WTA (2009) Beyond recist: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35:309-321
7. Eklund S, Nygren R, Larsson R (1998) Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro. Anti-Cancer Drugs 9:531-538 (Pubitemid 28346502)
8. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330-337
9. Fang Y, Sullivan R, Graham CH (2007) Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 313:867-877 (Pubitemid 46273437)
10. Gatenby RA, Gillies RJ (2007) Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 39:1358-1366 (Pubitemid 47031043)
11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects on the anthracycline antibiotics adriamycin and daunomycin. Biochem Pharmacol 57: 727-741 (Pubitemid 29094544)
12. Hafner F (2000) Cytosensor microphysiometer: technology and recent applications. Biosens Bioelectron 15:149-158 (Pubitemid 30484069)
13. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461-463
14. Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180 (Pubitemid 44881199)
15. Henning T, Brischwein M, Baumann W, Ehret R, Freund I, Kammerer R, Lehmann M, Schwinde A, Wolf B (2001) Approach to a multiparametric sensor-chip based tumor chemosensitivity assay. Anti-Cancer Drugs 12:21-32 (Pubitemid 32142280)
16. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703-707
17. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's achilles0 heel. Cancer Cell 13:472-482 (Pubitemid 351766797)
18. Mattern J, Volm M (1982) Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev 9:267-298 (Pubitemid 13126202)
19. McAlphine JN, Eisenkop SM, Spirtos NM (2008) Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 110:360-364
20. Mestres P, Morguet A (2009) The bionas technology for anticancer drug screening. Expert Opin Drug Discov 4:785-797
21. Mestres P, Morguet A, Schmidt W, Kob A, Thedinga E (2006) A new method to assess drug sensitivity on breast tumor acute slices preparation. Ann NY Acad Sci 1091:460-469 (Pubitemid 47092258)
22. Metzger R, Deglmann CJ, Hoerrlein S, Zapf S, Hilfrich J (2001) Towards in vitro prediction of an in vivo cytostatic response of human tumor cells with a fast chemosensitivity assay. Toxicology 166:97-108 (Pubitemid 32772775)
23. Nagourney RA (2006) Ex vivo programmed cell death and the prediction of response to chemotherapy. Curr Treat Options Oncol 7:103-110
24. Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5:1597-1601 (Pubitemid 44285243)
25. Owicki JC, Parce JW (1992) Biosensors based on the energy metabolism of living cells: the physical chemistry and cell biology of extracellular acidification. Biosens Bioelectron 7:255-272
26. Petersen L (2003) Wirkspiegel des ifosfamidmetaboliten chloracetaldehyd im verhältnis zu den thiolen cystein, glutathion und mesna im blut und in menschlichen tumorxenograften bei der nacktmaus. Inauguraldissertation, Universität Lübeck
27. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443 (Pubitemid 44050138)
28. Rustum YM, Slocum HK (1988) Predictive tests for cancer chemotherapy and the problem of tumor cell heterogeneity. Prog Clin Biol Res 276:119-137
29. Tomida A, Tsuruo T (1999) Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anti-Cancer Drug Design 14:169-177 (Pubitemid 29292313)
30. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M (2010) Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. PNAS 107:8352-8356
31. van Nijsten NW (2009) Hypothesis: using the warburg effect against cancer by reducing glucose and providing lactate. Med Hypthesis 73:48-51
32. Wolf B, Brischwein M, Baumann W, Ehret R, Henning T, Lehmann M, Schwinde A (1998) Microsensor-aided measurements of cellular signalling and metabolism on tumor cells: the cell monitoring system (CMS). Tumor Biol 19:374-383 (Pubitemid 28384463)
33. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrwell J, Teich J, Chomicz S, Ferrick DA (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292:C125-C136 (Pubitemid 46115126)